BL-M05D1 for advanced stomach cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with advanced or metastatic gastric (stomach) or gastroesophageal junction adenocarcinoma that has grown despite first-line treatment
- Cancer must have measurable tumors on imaging and tissue must be available for testing
- Good overall health (ECOG performance status 0 or 1, meaning you can do most daily activities)
- Heart, liver, kidney, and blood clotting function must be normal or near-normal
- No active infections, uncontrolled high blood pressure, severe heart disease, or other active cancers within 3 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.